research reports and media, page-2309

Hello everyone.

I just viewed most of the Johnson and Johnson virtualPharmaceutical BusinessReview 2021 general session.Most of the talk was about the breakup of the Consumer and Pharmaceutical divisions.

Why?We have a lot of time while we wait for results, and I mentioned J+J before in a post.And since they own the Elmiron product, I thought that it would be interesting to give them a closer look as we develop Zilosul.Just out of curiosity.

The short items of possibleinterest for Paradigmers, are these things which were repeated by differentpanelists:

1-They are a company that looks for new products that address an unmet need.

2-They aim for cures as well as for treatment.

3-Their pricing history has been keeping prices lower, and making their money on high volume.

Nothing was mentioned aboutspecific future drugs that I heard, but I’ll check out the taped session whenreleased to listen to the whole thing.I am not expecting anything about OA in particular, but just wanted to start “getting to know them better”.(I am not invested in J+Jor Janssen stock)

HC editing leaves a lot to be desired.